Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
Affymax logo — Pioneering innovative therapies for life-threatening conditi...

Affymax

Pioneering innovative therapies for life-threatening conditions, aiming to enhance anemia treatment in chronic kidney disease patients.

Founded 2001 51-200 employees Venture round Total: $173.00M Biopharma, Biotechnology +1

General Information

Company Name Affymax
Founded Year 2001
Founders / Decision Makers
Team member
Employees 51-200
Industries Biopharma, Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Affymax. To contact Affymax, visit affymax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Affymax compare?

A PDF of Affymax and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Affymax soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Affymax

Affymax is a biopharmaceutical company founded in 2001 with a focus on pioneering innovative therapies for life-threatening conditions. Their flagship product candidate, peginesatide (previously known as Hematide™), has completed Phase 3 trials for treating anemia in chronic kidney disease (CKD) patients. The company has recently received a $42.00M Venture Round investment on March 3, 2009 from investors Bessemer Venture Partners, Sprout Group, ProQuest. Affymax's ambition to enhance anemia treatment for CKD patients underlines its positioning in the Biopharma, Biotechnology, and Health Care industries. The company's current focus is on obtaining approval from the U.S. Food and Drug Administration (FDA) for peginesatide to address anemia in adult CKD patients on dialysis.

Business keywords: biopharmaceutical company, drug development, innovative therapies, anemia treatment, chronic kidney disease, peginesatide, Phase 3 trials, FDA review, New Drug Application, life-threatening conditions, dialysis patients

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $42.00M 3
Bessemer Venture Partners Sprout Group
Bessemer Venture Partners, Sprout Group +1
03 Mar 2009
Series D $60.00M 7
Bessemer Venture Partners Jafco Ventures Apax Partners
Bessemer Venture Partners, Jafco Ventures +5
18 Jul 2005
Series C $20.00M -
14 Apr 2004
Private Equity Round $51.00M -
30 Jul 2001

Affymax Alternatives & Competitors

View All Alternatives
Affymax vs
Cara Therapeutics
Cara Therapeutics United States

Transforming the way pruritus is treated to bring quality to the lives of those who suffer

Post-IPO Debt
46 employees
Biotechnology, Health Care
Compare Affymax vs Cara Therapeutics
Affymax vs
Agennix
Agennix

Crafting novel therapies to enhance the length and quality of life for seriously ill patients worldw...

Venture round
Biopharma, Biotechnology
Affymax vs
American Renal Associates
American Renal Associates United States

Working together to provide the highest quality care.

Venture round
1333 employees
Biotechnology, Health Care
View all alternatives

FAQ About Affymax

Pioneering innovative therapies for life-threatening conditions, aiming to enhance anemia treatment in chronic kidney disease patients.
Affymax was founded in 2001.
Affymax operates in Biopharma, Biotechnology and Health Care. Its work centres on biopharmaceutical company, drug development, innovative therapies and anemia treatment.
Affymax has approximately 51-200 employees.
Affymax has completed 4 funding rounds, raising a total of $173.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Affymax include Cara Therapeutics, Agennix, American Renal Associates, Scout Bio, Ocera Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Affymax and Cara Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Affymax, https://bouncewatch.com/company/affymax, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout